The Maharashtra Food and Drugs Administration (FDA) has detected 25 not-of-standard drugs during the month of February in the random sample testing. Seven of these products belong to the manufacturers of the tax-free state of Himachal Pradesh and 6 from Uttaranchal.
Some of the companies whose products were found to be not of standard are Valence Healthcare (Ginzin capsule), Endolabs Limited (Haloperidol tablets and cefadroxil oral suspension), Rhydburg Pharmaceuticals Ltd (Becoplex Forte), Ravian Lifesciences Pvt Ltd (Bone-C).
Some of other companies with products of not-of-standard drugs' and not complying with IP requirements are Baader Schulz Laboratories (Omeprazole capsules), Sehat Pharma Pvt Ltd (Cefim-dt tablets), Srishti Biotech (Detadine germicide solution), Lucent Biotech Ltd (Onset-4 tablets), Regent Healtcare Limited (Reblar tablets) and Rhydburg Pharmaceuticals Ltd (Collend tablets).
During February, other companies in the list include Goba Pharmaceuticals from Andhra Pradesh, Baader Schulz Laboratories from Daman, Navkar Formulations and Sehat Pharma Pvt Ltd from Gujarat, Athens Labs Ltd, Laborate Pharmaceuticals India Ltd, Shiva Bio-genetic Pharmaceuticals Ltd, Srishti Biotech, Swiss Garnier Life Sciences, Theon Pharmaceuticals Ltd and Valence Healthcare from Himachal Pradesh, Endolabs Limited and Sun-AJ Pharma from Madhya Pradesh, Twilight Litaka Pharma Limited from Maharashtra, G S Pharbutor Pvt Ltd from Rajasthan, US Vitamin Limited from Karnataka, Rhydburg Pharmaceuticals Ltd from Uttar Pradesh, Aglowmed Ltd, Lucent Biotech Ltd, Ravian Life science Pvt Ltd, Regent Healthcare Limited, Rhydburg Pharmaceuticals Ltd and Syncom Healthcare Limited from Uttaranchal.